RU2002124599A - Фармацевтическая композиция - Google Patents
Фармацевтическая композицияInfo
- Publication number
- RU2002124599A RU2002124599A RU2002124599/15A RU2002124599A RU2002124599A RU 2002124599 A RU2002124599 A RU 2002124599A RU 2002124599/15 A RU2002124599/15 A RU 2002124599/15A RU 2002124599 A RU2002124599 A RU 2002124599A RU 2002124599 A RU2002124599 A RU 2002124599A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- pyrimidinyl
- phenylethanesulfonamide
- methoxyphenoxy
- methoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (9)
1. Фармацевтическая композиция для уменьшения боли при эндотелин-индуцированном заболевании, причем эта фармацевтическая композиция содержит N-[6-метокси-5-(2-метоксифенокси)-2-(2-пиримидинил)-4-пиримидинил]-2-фенилэтенсульфонамид или его фармацевтически приемлемую соль в качестве эффективного компонента.
2. Фармацевтическая композиция по п.1, где эндотелин-индуцированным заболеванием является рак простаты.
3. Фармацевтическая композиция для облегчения остеогенных заболеваний, причем эта фармацевтическая композиция содержит N-[6-метокси-5-(2-метоксифенокси)-2-(2-пиримидинил)-4-пиримидинил]-2-фенилэтенсульфонамид или его фармацевтически приемлемую соль в качестве эффективного компонента.
4. Фармацевтическая композиция для уменьшения боли, сопровождающей остеогенез, причем эта фармацевтическая композиция содержит N-[6-метокси-5-(2-метоксифенокси)-2-(2-пиримидинил)-4-пиримидинил]-2-фенилэтенсульфонамид или его фармацевтически приемлемую соль в качестве эффективного компонента.
5. Фармацевтическая композиция для уменьшения боли, сопровождающей костные метастазы при раке простаты, причем эта фармацевтическая композиция содержит N-[6-метокси-5-(2-метоксифенокси)-2-(2-пиримидинил)-4-пиримидинил]-2-фенилэтенсульфонамид или его фармацевтически приемлемую соль в качестве эффективного компонента.
6. Фармацевтическая композиция для облегчения остеогенных заболеваний, связанных с костными метастазами при раке простаты, причем эта фармацевтическая композиция содержит N-[6-метокси-5-(2-метоксифенокси)-2-(2-пиримидинил)-4-пиримидинил]-2-фенилэтенсульфонамид или его фармацевтически приемлемую соль в качестве эффективного компонента.
7. Фармацевтическая композиция для подавления роста раковых клеток рака простаты, причем эта фармацевтическая композиция содержит N-[6-метокси-5-(2-метоксифенокси)-2-(2-пиримидинил)-4-пиримидинил]-2-фенилэтенсульфонамид или его фармацевтически приемлемую соль в качестве эффективного компонента.
8. Фармацевтическая композиция для подавления роста раковых клеток по п.1, где рак простаты является гормононезависимым раком простаты.
9. Фармацевтическая композиция для подавления прогрессии рака простаты, причем эта фармацевтическая композиция содержит N-[6-метокси-5-(2-метоксифенокси)-2-(2-пиримидинил)-4-пиримидинил]-2-фенилэтенсульфонамид или его фармацевтически приемлемую соль в качестве эффективного компонента.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000037313 | 2000-02-16 | ||
| JP2000-37314 | 2000-02-16 | ||
| JP2000-37313 | 2000-02-16 | ||
| JP2000037314 | 2000-02-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2002124599A true RU2002124599A (ru) | 2004-03-10 |
Family
ID=26585418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002124599/15A RU2002124599A (ru) | 2000-02-16 | 2000-10-27 | Фармацевтическая композиция |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6774131B1 (ru) |
| EP (1) | EP1256344B1 (ru) |
| JP (2) | JP3832229B2 (ru) |
| KR (1) | KR20020075797A (ru) |
| CN (1) | CN1434715A (ru) |
| AR (1) | AR031679A1 (ru) |
| AT (1) | ATE348617T1 (ru) |
| AU (1) | AU2000279614A1 (ru) |
| BR (1) | BR0017120A (ru) |
| CA (1) | CA2395711A1 (ru) |
| DE (1) | DE60032517T2 (ru) |
| ES (1) | ES2277856T3 (ru) |
| HU (1) | HUP0204139A3 (ru) |
| RU (1) | RU2002124599A (ru) |
| WO (1) | WO2001060370A1 (ru) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| GB0219660D0 (en) * | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| BRPI0806418A2 (pt) * | 2007-02-09 | 2011-09-06 | Poniard Pharmaceuticals Inc | formas de dosagem oral para picoplatina, série de granulados revestidos, processo para preparar uma forma de dosagem oral para picoplatina e métodos de tratamentos do cáncer |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| WO2009011861A1 (en) * | 2007-07-16 | 2009-01-22 | Poniard Pharmaceuticals, Inc. | Oral formulations for picoplatin |
| AU2009210654A1 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Use of picoplatin and bevacizumab to treat colorectal cancer |
| EP2294056A1 (en) * | 2008-05-23 | 2011-03-16 | Synthon B.V. | Bosentan salts |
| US20140105918A1 (en) | 2012-10-12 | 2014-04-17 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW414792B (en) | 1995-12-20 | 2000-12-11 | Yamanouchi Pharma Co Ltd | An arylethensulfonamide derivative having endothelin receptor antagonistic effect and its pharmaceutical composition |
| US6030975A (en) * | 1997-03-14 | 2000-02-29 | Basf Aktiengesellschaft | Carboxylic acid derivatives, their preparation and use in treating cancer |
| US6673832B1 (en) * | 1998-05-04 | 2004-01-06 | Gudarz Davar | Methods for identifying compounds for treating pain |
-
2000
- 2000-10-27 WO PCT/JP2000/007573 patent/WO2001060370A1/ja active IP Right Grant
- 2000-10-27 AR ARP000105669A patent/AR031679A1/es not_active Application Discontinuation
- 2000-10-27 AU AU2000279614A patent/AU2000279614A1/en not_active Abandoned
- 2000-10-27 DE DE60032517T patent/DE60032517T2/de not_active Expired - Fee Related
- 2000-10-27 CA CA002395711A patent/CA2395711A1/en not_active Abandoned
- 2000-10-27 BR BR0017120-4A patent/BR0017120A/pt not_active IP Right Cessation
- 2000-10-27 JP JP2000328374A patent/JP3832229B2/ja not_active Expired - Fee Related
- 2000-10-27 US US10/181,489 patent/US6774131B1/en not_active Expired - Fee Related
- 2000-10-27 HU HU0204139A patent/HUP0204139A3/hu active IP Right Revival
- 2000-10-27 ES ES00970160T patent/ES2277856T3/es not_active Expired - Lifetime
- 2000-10-27 CN CN00818938A patent/CN1434715A/zh active Pending
- 2000-10-27 EP EP00970160A patent/EP1256344B1/en not_active Expired - Lifetime
- 2000-10-27 AT AT00970160T patent/ATE348617T1/de not_active IP Right Cessation
- 2000-10-27 KR KR1020027010589A patent/KR20020075797A/ko not_active Application Discontinuation
- 2000-10-27 RU RU2002124599/15A patent/RU2002124599A/ru not_active Application Discontinuation
-
2006
- 2006-03-29 JP JP2006090667A patent/JP2006176542A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20020075797A (ko) | 2002-10-05 |
| WO2001060370A1 (fr) | 2001-08-23 |
| HUP0204139A3 (en) | 2003-07-28 |
| AU2000279614A1 (en) | 2001-08-27 |
| EP1256344B1 (en) | 2006-12-20 |
| CN1434715A (zh) | 2003-08-06 |
| EP1256344A4 (en) | 2004-12-29 |
| ES2277856T3 (es) | 2007-08-01 |
| DE60032517D1 (de) | 2007-02-01 |
| EP1256344A1 (en) | 2002-11-13 |
| DE60032517T2 (de) | 2007-10-04 |
| JP3832229B2 (ja) | 2006-10-11 |
| US6774131B1 (en) | 2004-08-10 |
| JP2006176542A (ja) | 2006-07-06 |
| ATE348617T1 (de) | 2007-01-15 |
| BR0017120A (pt) | 2003-01-14 |
| HUP0204139A2 (en) | 2003-05-28 |
| JP2001302514A (ja) | 2001-10-31 |
| CA2395711A1 (en) | 2002-07-18 |
| AR031679A1 (es) | 2003-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002124599A (ru) | Фармацевтическая композиция | |
| AP2001002319A0 (en) | Pyrimidine-2,4,6-trione metalloproteinase inhibitors. | |
| LU92602I2 (fr) | Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci | |
| EP1426375A3 (en) | Analgesic spiroindole derivatives | |
| EP1485381B8 (en) | Azolylaminoazine as inhibitors of protein kinases | |
| ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE365733T1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
| SG166827A1 (en) | Aminopyrimidines useful as kinase inhibitors | |
| CA2399358A1 (en) | Pyrrole substituted 2-indolinone protein kinase inhibitors | |
| CA2349142A1 (en) | Compositions and methods for stimulating gastrointestinal motility | |
| DE60020825D1 (de) | Pharmazeutische zusammensetzungen die dipeptidylpeptidase iv inhibitoren enthalten zur förderung des wachstums | |
| HK1096673A1 (en) | Compositions useful as inhibitors of protein kinases | |
| YU6602A (sh) | Pirimidin-2,4,6-trion metaloproteinazni inhibitori | |
| MA28583B1 (fr) | Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
| IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
| YU84102A (sh) | Nova dibenzoazulen jedinjenja kao inhibitori faktora nekroze tumora | |
| AU1182702A (en) | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | |
| WO2007075572A3 (en) | Orally active purine-based inhibitors of heat shock protein 90 | |
| DK1268472T3 (da) | 3-aminopyrazolinhibitorer af cyclinafhængige kinaser | |
| CA2364178A1 (en) | N-benzenesulfonyl l-proline compounds as bradykinin antagonists | |
| WO2003082199A3 (en) | Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents | |
| PL364936A1 (en) | Use of bioactive metabolites of gepirone for the treatment of psychological disorders | |
| WO2001089538A3 (en) | Apoptotic entities for use in treatment of endothelium dysfunction disorders | |
| BG106700A (en) | Sodium 2-(4,6-dimethylpyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl) ethoxy-3,3-diphenylpropionate and use thereof as endothelin antagonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20050322 |